Brokerages Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Price Target at $158.69

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have received an average recommendation of “Buy” from the seventeen brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $158.6875.

Several equities research analysts have recently issued reports on the stock. Truist Financial increased their price objective on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Stifel Nicolaus increased their target price on Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, November 24th. Craig Hallum initiated coverage on Palvella Therapeutics in a research note on Thursday, December 4th. They issued a “buy” rating and a $175.00 price target on the stock. Raymond James Financial reaffirmed a “strong-buy” rating and set a $193.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Finally, Mizuho initiated coverage on Palvella Therapeutics in a report on Wednesday, January 7th. They set an “outperform” rating and a $205.00 price objective for the company.

Palvella Therapeutics Stock Performance

Shares of PVLA stock opened at $82.33 on Friday. Palvella Therapeutics has a 52 week low of $17.31 and a 52 week high of $114.69. The company’s 50 day moving average price is $91.86 and its two-hundred day moving average price is $76.72. The company has a market capitalization of $974.79 million, a P/E ratio of -31.30 and a beta of -0.16.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 20.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PVLA. Millennium Management LLC acquired a new stake in Palvella Therapeutics in the 1st quarter valued at $7,553,000. Goldman Sachs Group Inc. bought a new position in shares of Palvella Therapeutics in the 1st quarter valued at about $533,000. Geode Capital Management LLC increased its position in shares of Palvella Therapeutics by 84.7% in the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock valued at $3,923,000 after acquiring an additional 79,787 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in Palvella Therapeutics during the second quarter worth about $37,000. Finally, JPMorgan Chase & Co. raised its holdings in Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after acquiring an additional 3,242 shares in the last quarter. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.